drug
ferric derisomaltose
Marketedupdated 4mo agoby Pharmacosmos Therapeutics Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying ferric derisomaltose
- phase4Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
- phase3Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia
- phase3Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
- phase4The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery
- phase4Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
- phase4A Clinical Trial Assessing the Efficacy of Intravenous Iron for the Treatment of Anemia Following Cardiac Surgery
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 25, 2029
~2.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Jun 22, 2036method-of-use (U-3594)US 11633489
- Jun 22, 2036method-of-use (U-3594)US 11633489
- Jun 22, 2036method-of-use (U-3594)US 11633489
- Aug 14, 2029compositionUS 88153013.0y
- Aug 14, 2029compositionUS 88153013.0y
- Aug 14, 2029compositionUS 88153013.0y
- Mar 25, 2029compositionUS 104148312.6y
- Mar 25, 2029compositionUS 104148312.6y
- Mar 25, 2029compositionUS 104148312.6y
- Mar 25, 2029compositionUS 118515042.6y
- Mar 25, 2029compositionUS 118515042.6y
- Mar 25, 2029compositionUS 118515042.6y
- Mar 25, 2029compositionUS 120309622.6y
- Mar 25, 2029compositionUS 120309622.6y
- Mar 25, 2029compositionUS 120309622.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that